Real IntelligenceReviewIndependent Clinical Evaluation
Back to Atlas

Diagnostic imaging

Viz LVO

Viz.ai

Analyzes CT angiography for suspected large vessel occlusion and supports stroke-team triage and notification.

Designed for

Stroke team and radiologist

Care setting

Hospital

Specialty

Neuroradiology, Stroke care

Public evidence assessedReviewed August 31, 2026

Our assessment

Bottom line

Viz LVO has a credible regulatory foundation for its defined triage use and evidence that addresses both detection and notification speed. The remaining uncertainty is whether the current deployed version produces the same benefit across a specific network's scanners, patients, and stroke workflow.

Based on public sources. RIR did not independently test this product. This is not an endorsement or recommendation.

What the evidence supports

Reviewed sources establish software intended to flag suspected LVO findings and notify qualified clinicians.

What remains uncertain

Current-version performance across scanners, sites, prevalence conditions, and downstream treatment pathways requires local evaluation.

How it was studied

The FDA De Novo review describes a retrospective study comparing algorithm detections with neuroradiologist ground truth and comparing standard-of-care CTA-to-notification time with the software-assisted workflow.

Product facts

Intended use
Flag suspected large vessel occlusion on eligible imaging and support timely specialist review and coordination.
Represented version
FDA-authorized device family; current deployed version requires confirmation
Regulatory context
The Viz LVO device family received FDA De Novo authorization. Exact cleared scope and deployed version require confirmation.

Sources reviewed

2 public sources represented in this evidence profile.

FDA De Novo review for Viz LVORegulatoryViz neurovascular product overviewOfficial product
For clinical and investment reviewEvidence context and questions for deeper review

Evidence source base

FDA regulatory review and official product materials. Current deployed version and later clearances must be reconciled before local testing.

Important limitation

Regulatory performance for a defined device version does not establish current local sensitivity, false-alert burden, scanner transportability, treatment times, or patient outcomes.

Questions to ask

  1. 01What is local sensitivity at the treated vessel locations?
  2. 02How are false negatives audited?
  3. 03Does alerting change time to treatment in this network?
Return to AtlasHow RIR evaluates evidence